Jump to content

Etrolizumab: Difference between revisions

Browse history interactively
Page 1
Page 2
← Previous edit
Content deleted Content added
VisualWikitext
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number').
mNo edit summary
 
(56 intermediate revisions by 32 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 450065874
| verifiedrevid = 457121719
| type = mab
| type = mab
| image =
| image =
Line 7: Line 9:
| mab_type = mab
| mab_type = mab
| source = zu/a
| source = zu/a
| target = integrin α7β7
| target = β7 subunit of α4β7 and αEβ7 integrin heterodimers
| tradename =
| tradename =
| Drugs.com =
| Drugs.com =
Line 14: Line 16:
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category=
| pregnancy_category=
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
Line 25: Line 27:
| elimination_half-life =
| elimination_half-life =
| excretion =
| excretion =
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = <!-- blanked - oldvalue: 1044758-60-2 -->
| CAS_number = 1044758-60-2
| ATC_prefix = none
| ATC_prefix = none
| ATC_suffix =
| ATC_suffix =
Line 34: Line 36:
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| DrugBank =
| C=6396 | H=9874 | N=1702 | O=2010 | S=42
| IUPHAR_ligand = 8407 | C=6396 | H=9874 | N=1702 | O=2010 | S=42
| molecular_weight = 144.1 kDa
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = NA
| ChemSpiderID = none
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D09901
}}
}}


'''Etrolizumab''' (rhuMAb Beta7) is a [[biopharmaceutical]] drug candidate being developed for the treatment of [[ulcerative colitis]] and [[Crohn's disease]]. It is a humanized monoclonal antibody against the [[ITGB7|β7 subunit]] of [[integrin]]s α4β7 and αEβ7.<ref>Adis Insight [http://adisinsight.springer.com/drugs/800026082 Etrolizumab] {{Webarchive|url=https://web.archive.org/web/20160603093535/http://adisinsight.springer.com/drugs/800026082 |date=2016-06-03 }} Latest Information Update: 16 Dec 2015</ref> Etrolizumab was developed by [[Genentech]]<ref name=ukmi>UK Medicines Information. [http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6112 etrolizumab at UKMI] {{Webarchive|url=https://web.archive.org/web/20160604005122/http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6112 |date=2016-06-04 }} Page accessed May 10, 2016</ref><ref>{{Cite web|url=https://www.gene.com/medical-professionals/pipeline|title=Genentech: Our Pipeline|website=www.gene.com|access-date=2020-05-22|archive-date=2020-05-24|archive-url=https://web.archive.org/web/20200524223812/https://www.gene.com/medical-professionals/pipeline|url-status=live}}</ref> by engineering the FIB504 antibody to include human IgGl-heavy chain and κ-light chain frameworks; it is manufactured in [[Chinese hamster ovary cell|CHO cells]].<ref>{{cite patent | country = WO | number = 2012135589 | title = Methods of administering beta7 integrin antagonists | assign1 = Genentech and Roche}} For the FIB504 mAb, see Andrew DP et al. Distinct but overlapping epitopes are involved in alpha 4 beta 7-mediated adhesion to vascular cell adhesion molecule-1, mucosal addressin-1, fibronectin, and lymphocyte aggregation. {{cite journal | vauthors = Andrew DP, Berlin C, Honda S, Yoshino T, Hamann A, Holzmann B, Kilshaw PJ, Butcher EC | title = Distinct but overlapping epitopes are involved in alpha 4 beta 7-mediated adhesion to vascular cell adhesion molecule-1, mucosal addressin-1, fibronectin, and lymphocyte aggregation | journal = Journal of Immunology | volume = 153 | issue = 9 | pages = 3847–61 | date = November 1994 | doi = 10.4049/jimmunol.153.9.3847 | pmid = 7523506 | s2cid = 32434092 }} as referenced in paragraph 146 of the PCT application.</ref>
'''Etrolizumab''' is a humanized monoclonal antibody designed for the treatment of [[inflammatory bowel disease]].<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Etrolizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/etrolizumab.pdf}}</ref>


As of 2016, it was in phase III studies for induction and maintenance therapy in people with ulcerative colitis and Crohn's.<ref name=ukmi/><ref name="pmid26914639">{{cite journal | vauthors = Makker J, Hommes DW | title = Etrolizumab for ulcerative colitis: the new kid on the block? | journal = Expert Opinion on Biological Therapy | volume = 16 | issue = 4 | pages = 567–72 | date = 2016 | pmid = 26914639 | doi = 10.1517/14712598.2016.1158807 | s2cid = 24706213 }}</ref><ref name="pmid26630451">{{cite journal | vauthors = Rosenfeld G, Parker CE, MacDonald JK, Bressler B | title = Etrolizumab for induction of remission in ulcerative colitis | journal = The Cochrane Database of Systematic Reviews | issue = 12 | pages = CD011661 | date = December 2015 | volume = 2015 | pmid = 26630451 | doi = 10.1002/14651858.CD011661.pub2 | pmc = 8612697 }}</ref> According to data of one meta-analysis efficacy of Etrolizumab is comparable with conventional therapies such as Infliximab with less adverse events.<ref name="pmid30395950">{{cite journal | vauthors = Motaghi E, Ghasemi-Pirbaluti M, Zabihi M | title = Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison|url=https://www.researchgate.net/publication/328722610 | journal = Pharmacological Research | volume = 139 | pages = 120–125 | date = January 2019 | pmid = 30395950 | doi = 10.1016/j.phrs.2018.11.003 | s2cid = 53235342 }}</ref>
Etrolizumab was developed by [[Genentech]].

Phase III clinical trials produced mixed results; and, on October 14, 2020, [[Hoffmann-La Roche]], the parent company of [[Genentech]], abandoned further efforts to develop etrolizumab for [[ulcerative colitis]], but continued development for [[Crohn's disease]],<ref>{{cite journal |last1=Tong |first1=Amber |title=Roche writes off ulcerative colitis portion of etrolizumab program, days after dissecting PhIII setback |journal=Endpoints |date=October 15, 2020 |url=https://endpts.com/roche-writes-off-ulcerative-colitis-portion-of-etrolizumab-program-days-after-dissecting-phiii-setback |access-date=2 January 2021 |archive-date=24 November 2020 |archive-url=https://web.archive.org/web/20201124012928/https://endpts.com/roche-writes-off-ulcerative-colitis-portion-of-etrolizumab-program-days-after-dissecting-phiii-setback/ |url-status=live }}</ref> until disappointing trial results led to this being abandoned too in February 2022.<ref>{{cite web |url=https://www.fiercebiotech.com/biotech/roche-lets-go-etro-dumping-phase-3-crohn-s-prospect-18-months-after-posting-weak-colitis |website=Fierce Biotech |access-date=8 March 2023 |title=Archived copy |archive-date=8 March 2023 |archive-url=https://web.archive.org/web/20230308012715/https://www.fiercebiotech.com/biotech/roche-lets-go-etro-dumping-phase-3-crohn-s-prospect-18-months-after-posting-weak-colitis |url-status=live }}</ref>


== References ==
== References ==
{{Reflist}}

<references/>


{{monoclonals for immune system}}
{{monoclonals for immune system}}

[[Category:Monoclonal antibodies]]




Retrieved from "https://en.wikipedia.org/wiki/Special:ComparePages"